Eli Lilly presented new Phase 3 cardiovascular outcomes data for Foundayo (orforglipron), its oral GLP-1 receptor agonist, at the European Association for the Study of Diabetes (EASD) 2026 annual meeting on September 15, 2026. The trial, called ACHIEVE-4, is the first cardiovascular-outcomes readout for this once-daily pill, and it adds a new data point to the fast-moving oral GLP-1 category.
What Foundayo Is
Foundayo is the brand name for orforglipron, a small-molecule (non-peptide-mimetic) GLP-1 receptor agonist taken as a once-daily tablet with no food or water restrictions, unlike earlier oral GLP-1 products. The FDA approved it for weight management in adults with obesity, or overweight adults with at least one weight-related condition. That approval, covered separately on this site, was based on trials showing meaningful weight loss; ACHIEVE-4 is a different, newer trial looking specifically at heart-related outcomes in people with type 2 diabetes.
What the ACHIEVE-4 Trial Found
ACHIEVE-4 enrolled adults with type 2 diabetes and elevated cardiovascular risk and compared Foundayo against insulin glargine, a standard injectable diabetes treatment, as add-on therapy. According to data presented at EASD, Foundayo met its primary goal of non-inferiority to insulin glargine on a composite cardiovascular endpoint. Beyond that baseline goal, the trial reported a 16% lower relative risk of MACE-4 events and a 23% lower relative risk of MACE-3 events compared with insulin glargine.
MACE (major adverse cardiovascular events) is a standard composite endpoint used in cardiovascular safety trials. MACE-3 typically bundles cardiovascular death, non-fatal heart attack, and non-fatal stroke; MACE-4 adds a fourth component, often hospitalization for unstable angina or a coronary revascularization procedure, depending on the trial's exact definition. Composite endpoints like these let researchers detect a treatment effect without needing an enormous sample size, at the cost of not telling you which specific event driven the result without digging into the underlying data.
Why This Is Human Trial Data, and What It Isn't Yet
This is randomized, controlled, human clinical trial evidence, not an animal or preclinical study, and it comes from a registered Phase 3 program rather than a small pilot. That said, a conference presentation is not the same as a completed regulatory review: full peer-reviewed publication and FDA review of any label change take additional time, and Foundayo's current FDA approval is for weight management, not specifically for cardiovascular risk reduction. Anyone considering Foundayo for cardiovascular reasons should understand that distinction and discuss it with their own physician rather than assuming an expanded label is already in place.
Context: A Crowded News Day for Lilly's Pipeline
Lilly used the same EASD presentation to share updates on two other cardiometabolic programs: further data from retatrutide's TRIUMPH program and early Phase 2 results combining eloralintide with tirzepatide, both of which are covered in dedicated articles elsewhere on this site. The cluster of announcements reflects how much clinical-trial activity is currently concentrated in the GLP-1 and related incretin space, with multiple companies racing to report cardiovascular, kidney, and metabolic outcomes data on top of the weight-loss numbers that drove the category's initial growth.
The Bottom Line
ACHIEVE-4 is a genuine, dated clinical trial result, not a marketing claim: a Phase 3 study in people with type 2 diabetes and cardiovascular risk found Foundayo performed at least as well as, and on some measures better than, insulin glargine on cardiovascular event rates. It's encouraging data for an oral GLP-1 drug, but it describes a specific trial population and endpoint, not a general guarantee, and it does not change what Foundayo is currently FDA-approved to treat. Anyone with diabetes and cardiovascular risk factors should talk to their doctor about their own treatment options rather than drawing personal conclusions from a conference presentation.